Design of Cyclic Peptides - Peptide and Protein Design for Biopharmaceutical Applications - page 174

[162] M. Masuda et al ., A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-
Polyphemusin-II), Biochemical and Biophysical Research Communications , 189,
845-850 (1992).
[163] H. Tamamura et al ., Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr(5,12),
Lys(7)]-polyphemusin II), with the maintenance of anti-HIV activity and solution
structure, Bioorganic & Medicinal Chemistry , 6, 473-479 (1998).
[164] H. Tamamura et al ., A low-molecular-weight inhibitor against the chemokine
receptor CXCR4: A strong anti-HIV peptide T140, Biochemical and Biophysical
Research Communications , 253, 877-882 (1998).
[165] H. Tamamura et al ., Effective lowly cytotoxic analogs of an HIV-cell fusion
inhibitor, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), Bioorganic & Medicinal
Chemistry , 6, 231-238 (1998).
[166] H. Tamamura et al ., Pharmacophore identification of a specific CXCR4 inhibitor,
T140, leads to development of effective anti-HIV agents with very high selectivity
indexes, Bioorganic & Medicinal Chemistry Letters , 10, 2633-2637 (2000).
[167] N. Fujii et al ., Molecular-size reduction of a potent CXCR4-chemokine antagonist
using orthogonal combination of conformation- and sequence-based libraries,
Angewandte Chemie - International Edition , 42, 3251-3253 (2003).
[168] S. Ueda et al ., Structure-activity relationships of cyclic peptide-based chemokine
receptor CXCR4 antagonists: Disclosing the importance of side-chain and back-
bone functionalities, Journal of Medicinal Chemistry , 50, 192-198 (2007).
[169] G. Weckbecker et al ., Opportunities in somatostatin research: Biological, chemical
and therapeutic aspects, Nature Reviews Drug Discovery , 2, 999-1017 (2003).
[170] C. E. DiLiberti, The best targets for biogenerics, BioPharm International , 19,
50-52, 54, 56, 58, 60, 62, 64 (2006).
[171] D. F. Veber, et al ., A potent cyclic hexapeptide analog of somatostatin, Nature , 292,
55-58 (1981).